Skip NavigationSkip to Content
Return Return to Search Results

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors

  1. Author:
    Strauss, Julius
    Heery, Christopher R.
    Schlom, Jeffrey
    Madan, Ravi A.
    Cao, Liang
    Kang, Zhigang
    Lamping, Elizabeth
    Marte, Jennifer L.
    Donahue, Renee N.
    Grenga, Italia
    Cordes, Lisa
    Christensen, Olaf
    Mahnke, Lisa
    Helwig, Christoph
    Gulley, James L.

  2. Author Address

    NCI, Tumor Immunol & Biol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA.NCI, Mol Targets Core, Genet Branch, NIH, Bethesda, MD 20892 USA.Leidos Biomed Res Inc, Basic Sci Program, Frederick, MD USA.NCI, Off Res Nursing, NIH, Bethesda, MD 20892 USA.NIH, Dept Pharm, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.EMD Serono, Billerica, MA USA.Merck KGaA, Darmstadt, Germany.
    1. Year: 2018
    2. Date: Mar 15
  2. Journal: Clinical Cancer Research
  3. AMER ASSOC CANCER RESEARCH,
    1. 24
    2. 6
    3. Pages: 1287-1295
  5. Type of Article: Article
  6. ISSN: 1078-0432
  1. Abstract:

    Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a monoclonal antibody against programmed death ligand 1 (PD-L1) fused to a transforming growth factor-beta (TGF-beta) "trap."

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1078-0432.CCR-17-2653
  3. PMID: 29298798
  4. View record in Web of Science®
  5. WOS: 000427627400007

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel